Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

WAVE LIFE SCIENCES LTD.

(WVE)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Wave Life Sciences : Takeda Pharmaceutical Partially Amend Central Nervous System Collaboration Agreement

10/18/2021 | 05:29pm EST


ę MT Newswires 2021
All news about WAVE LIFE SCIENCES LTD.
11/10Wave Life Sciences Third Quarter 2021 Earnings Call
PU
11/10Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business U..
PU
11/10WAVE LIFE SCIENCES : Q3 Earnings Snapshot
AQ
11/10WAVE LIFE SCIENCES LTD. Management's Discussion and Analysis of Financial Condition an..
AQ
11/10Wave Life Sciences Ltd. Reports Earnings Results for the Third Quarter and Nine Months ..
CI
11/10WAVE LIFE SCIENCES LTD. : Results of Operations and Financial Condition, Regulation FD Dis..
AQ
11/10Earnings Flash (WVE) WAVE LIFE SCIENCES USA Reports Q3 Revenue $36.4M
MT
11/10Wave Life Sciences Reports Third Quarter 2021 Financial Results and Provides Business U..
GL
11/08Wave Life Sciences to Present at the Stifel 2021 Virtual Healthcare Conference
GL
11/01Wave Life Sciences to Webcast Conference Call of Third Quarter 2021 Financial Results o..
GL
More news
Analyst Recommendations on WAVE LIFE SCIENCES LTD.
More recommendations
Financials (USD)
Sales 2021 56,1 M - -
Net income 2021 -115 M - -
Net cash 2021 145 M - -
P/E ratio 2021 -1,73x
Yield 2021 -
Capitalization 229 M 229 M -
EV / Sales 2021 1,51x
EV / Sales 2022 0,97x
Nbr of Employees 219
Free-Float 96,0%
Chart WAVE LIFE SCIENCES LTD.
Duration : Period :
Wave Life Sciences Ltd. Technical Analysis Chart | WVE | SG9999014716 | MarketScreener
Technical analysis trends WAVE LIFE SCIENCES LTD.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Last Close Price 3,90 $
Average target price 9,86 $
Spread / Average Target 153%
EPS Revisions
Managers and Directors
Paul B. Bolno President, Chief Executive Officer & Director
Kyle Moran Chief Financial & Accounting Officer
Christian O. Henry Chairman
Chandra Vargeese Chief Technology Officer
Michael Panzara Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
WAVE LIFE SCIENCES LTD.-50.44%229
GILEAD SCIENCES, INC.18.31%86 465
BIONTECH SE331.48%84 953
WUXI APPTEC CO., LTD.28.27%66 734
REGENERON PHARMACEUTICALS31.76%66 553
VERTEX PHARMACEUTICALS-20.90%47 530